Assessing the Safety and Efficacy of Tranexamic Acid Usage in Osteogenesis Imperfecta Patients.
Journal
Journal of pediatric orthopedics
ISSN: 1539-2570
Titre abrégé: J Pediatr Orthop
Pays: United States
ID NLM: 8109053
Informations de publication
Date de publication:
01 Jan 2024
01 Jan 2024
Historique:
pubmed:
26
9
2023
medline:
26
9
2023
entrez:
26
9
2023
Statut:
ppublish
Résumé
Osteogenesis Imperfecta (OI) usually causes an increased fracture burden and bone deformity, with subsequent operations common. In addition to skeletal manifestations, there is a potential increase in bleeding susceptibility due to the increased frequency of orthopedic procedures, warranting investigation into methods to mitigate this risk. This study aims to evaluate the safety and efficacy of tranexamic acid (TXA) usage to reduce intraoperative blood loss in children with OI. We want to assess the potential benefits, risks, and complications involved with TXA use in this patient population. TXA-receiving patients (cases) were matched 1:1 with non-TXA-receiving controls on the following criteria: age within 2 years, bone category, and OI Type. Descriptive statistics were used to summarize the data. Fisher Exact Test was performed to compare transfusion status between groups. A Wilcoxon Rank Sum test was performed to assess differences between the groups in days of stay, length of surgery, and estimated blood loss (EBL). All analyses were conducted using SAS version 9.4. P <0.05 was considered statistically significant. Our TXA-receiving population of 30 patients consisted of 11 females and 19 males. One patient was OI type I, 13 were OI type III, 14 were OI type IV, and 2 were categorized as Other (not Type I through Type IV). We found a significant difference in transfusion status ( P =0.02), with zero TXA patients requiring a transfusion compared with 20% of the control cases. There is also a significant difference in median EBL ( P =0.0004) between groups, with TXA patients having decreased intraoperative EBL (20 vs. 62.5 mL). There was also a difference in median days of postoperative stay between TXA-receiving and non-TXA-receiving patients ( P =0.001; 2.6 vs. 4 d). Our study concluded that TXA use in OI patients is associated with lower perioperative transfusions and intraoperative blood loss rates. These results support the standard usage of TXA in these patients to reduce intraoperative blood loss. Level III.
Sections du résumé
BACKGROUND
BACKGROUND
Osteogenesis Imperfecta (OI) usually causes an increased fracture burden and bone deformity, with subsequent operations common. In addition to skeletal manifestations, there is a potential increase in bleeding susceptibility due to the increased frequency of orthopedic procedures, warranting investigation into methods to mitigate this risk. This study aims to evaluate the safety and efficacy of tranexamic acid (TXA) usage to reduce intraoperative blood loss in children with OI. We want to assess the potential benefits, risks, and complications involved with TXA use in this patient population.
METHODS
METHODS
TXA-receiving patients (cases) were matched 1:1 with non-TXA-receiving controls on the following criteria: age within 2 years, bone category, and OI Type. Descriptive statistics were used to summarize the data. Fisher Exact Test was performed to compare transfusion status between groups. A Wilcoxon Rank Sum test was performed to assess differences between the groups in days of stay, length of surgery, and estimated blood loss (EBL). All analyses were conducted using SAS version 9.4. P <0.05 was considered statistically significant.
RESULTS
RESULTS
Our TXA-receiving population of 30 patients consisted of 11 females and 19 males. One patient was OI type I, 13 were OI type III, 14 were OI type IV, and 2 were categorized as Other (not Type I through Type IV). We found a significant difference in transfusion status ( P =0.02), with zero TXA patients requiring a transfusion compared with 20% of the control cases. There is also a significant difference in median EBL ( P =0.0004) between groups, with TXA patients having decreased intraoperative EBL (20 vs. 62.5 mL). There was also a difference in median days of postoperative stay between TXA-receiving and non-TXA-receiving patients ( P =0.001; 2.6 vs. 4 d).
CONCLUSIONS
CONCLUSIONS
Our study concluded that TXA use in OI patients is associated with lower perioperative transfusions and intraoperative blood loss rates. These results support the standard usage of TXA in these patients to reduce intraoperative blood loss.
LEVEL OF EVIDENCE
METHODS
Level III.
Identifiants
pubmed: 37750572
doi: 10.1097/BPO.0000000000002524
pii: 01241398-990000000-00376
pmc: PMC10702696
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e73-e78Informations de copyright
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Rauch F, Glorieux FH. Osteogenesis imperfecta. The Lancet. 2004;363:1377–1385.
Orgel JPRO, San Antonio JD, Antipova O. Molecular and structural mapping of collagen fibril interactions. Connective tissue research. 2011;52:2–17.
Forlino A, Cabral WA, Barnes AM, et al. New perspectives on osteogenesis imperfecta. Nat Rev Endocrinoly. 2011;7:540–557.
Lafage-Proust MH, Courtois I. The management of osteogenesis imperfecta in adults: state of the art. Joint Bone Spine. 2019;86:589–593.
Gil JA, DeFroda SF, Sindhu K, et al. Challenges of fracture management for adults with osteogenesis imperfecta. Orthopedics. 2017;40:e17–e22.
Keegan MT, Whatcott BD, Harrison BA. Osteogenesis imperfecta, perioperative bleeding, and desmopressin. J Am Soc Anesthesiol. 2002;97:1011–1013; Cardone, D., & Klein, A. A. (2009).
Evensen SA, Myhre L, Stormorken H. Haemostatic studies in osteogenesis imperfecta. Scand J Haematol. 1984;33:177–179.
Hathaway WE, Solomons CC, Ott JE. Platelet function and pyrophosphates in osteogenesis imperfecta. Blood. 1972;39:500–509.
Sperry K. Fatal intraoperative hemorrhage during spinal fusion surgery for osteogenesis imperfecta. Am Forensic Med Pathol. 1989;10:54–59.
Siegel BM, Friedman A, Schwartz SO. Hemorrhagic disease in osteogenesis imperfecta. Am J Med. 1957;22:315–321.
Roberts I, Shakur H, Coats T, et al. The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients. Health Technol Ass (Winchester, England). 2013;17:1–79.
Hunt BJ. The current place of tranexamic acid in the management of bleeding. Anaesthesia. 2015;70:50–e18.
Cai J, Ribkoff J, Olson S, et al. The many roles of tranexamic acid: An overview of the clinical indications for TXA in medical and surgical patients. Eur J Haematol. 2020;104:79–87. https://doi.org/10.1111/ejh.13348
doi: 10.1111/ejh.13348
Ker K, Prieto-Merino D, Roberts I. Systematic review, meta-analysis and meta-regression of the effect of tranexamic acid on surgical blood loss. British J Surgery. 2013;100:1271–1279. https://doi.org/10.1002/bjs.9193
doi: 10.1002/bjs.9193
Xie J, Ma J, Yao H, et al. Multiple Boluses of Intravenous Tranexamic Acid to Reduce Hidden Blood Loss After Primary Total Knee Arthroplasty Without Tourniquet: A Randomized Clinical Trial. J Arthrop. 2016;31:2458–2464. https://doi.org/10.1016/j.arth.2016.04.034
doi: 10.1016/j.arth.2016.04.034
Urban D, Dehaeck R, Lorenzetti D, et al. Safety and efficacy of tranexamic acid in bleeding paediatric trauma patients: a systematic review protocol. BMJ open. 2016;6:e012947.
Eckert MJ, Wertin TM, Tyner SD, et al. Tranexamic acid administration to pediatric trauma patients in a combat setting: the pediatric trauma and tranexamic acid study (PED-TRAX. J Traum Acute Care Surg. 2014;77:852–858.
Tzatzairis T, McMahon S, Shilpa J, et al. Safety and efficacy of tranexamic acid in children with cerebral palsy undergoing femoral varus derotational osteotomy: a double cohort study. Eur J Orthop Surg Traumatol. 2020;30:1039–1044.
Zhang Y, Zhang X, Wang Y, et al. Efficacy and safety of tranexamic acid in pediatric patients undergoing cardiac surgery: a single-center experience. Front Pediatr. 2019;7:181.
Masrouha KZ, Shabin ZM, Bhutada K, et al. Impact of tranexamic acid on blood loss and transfusion rate in children with cerebral palsy undergoing hip reconstruction with two or more osteotomies. Eur J Orthop Surg Traumatol. 2022;32:287–291.
Compton E, Goldstein RY, Nazareth A, et al. Tranexamic acid use decreases transfusion rate in children with cerebral palsy undergoing proximal femoral varus derotational osteotomy. Medicine. 2022;101:e28506.
Majid I, Alshryda S, Somanchi B, et al. The Value of Tranexamic Acid in Reducing Blood Loss following Hip Reconstruction in Children with Cerebral Palsy. J Blood Trans. 2015;2015:827027. https://doi.org/10.1155/2015/827027
doi: 10.1155/2015/827027
Hancock GE, Price KR, Giles SN, et al. The effect of tranexamic acid on blood loss and transfusion requirement in intramedullary rodding for deformity correction in osteogenesis imperfecta. In Orthopaedic Proceedings. Br Editl Soc Bone Joint Surg. 2015;97(SUPP_9):17–17.
Nazareth A, Shymon SJ, Andras L, et al. Impact of tranexamic acid use on blood loss and transfusion rates following femoral varus derotational osteotomy in children with cerebral palsy. J Child Orthop. 2019;13:190–195.
Bower WF, Jin L, Underwood MJ, et al. Peri-operative blood transfusion increases length of hospital stay and number of postoperative complications in non-cardiac surgical patients. Hong Kong Med J. 2010;16:116–120; PMID: 20354245.
Taeuber I, Weibel S, Herrmann E, et al. Association of intravenous tranexamic acid with thromboembolic events and mortality: A Systematic Review, Meta-analysis, and Meta-regression. JAMA Surg. 2021;156:e210884. doi: 10.1001/jamasurg.2021.0884. Epub ahead of print PMID: 33851983; PMCID: PMC8047805.
doi: 10.1001/jamasurg.2021.0884.
Ewing MA, Huntley SR, Baker DK, et al. Blood transfusion during total ankle arthroplasty is associated with increased in-hospital complications and costs. Foot Ankle Spec. 2019;12:115–121.
Kumba C. “Transfusion in pediatric surgical settings: economic aspects and hospitalization costs”. Acta Sci Paediatr. 2021;4:03–06.
Persiani P, Pesce MV, Martini L, et al. Intraoperative bleeding in patients with osteogenesis imperfecta type III treated by Fassier-Duval femoral rodding: analysis of risk factors. J Pediatr Orthop B. 2018;27:338–343.